期刊文献+

乳腺癌分子分型与GSTM1、GSTT1和GSTP1(rs1695)基因多态性的关系及意义 被引量:8

The correlationship and its clinical significance between gene polymorphisms of GSTM1, GSTT1 and GSTP1 with molecular classification in breast cancer
下载PDF
导出
摘要 目的探讨乳腺癌患者谷胱甘肽转硫酶M1(GSTM1)、谷胱甘肽转硫酶T1(GSTT1)和谷胱甘肽转硫酶P1(GSTP1 rs1695)的基因多态性分布,并分析其与乳腺癌分子分型的关系。方法应用多重PCR技术(MPCR)和高分辨融解曲线技术(HRM)分析252例女性乳腺癌患者外周血中GSTM1、GSTT1和GSTP1(rs 1 695)的基因多态性。结果 252例乳腺癌患者中,108例(42.9%)为GSTM1(+),144例(57.1%)为GSTM1(-);178例(70.6%)为GSTT1(+),74例(29.4%)为GSTT1(-);143例(56.7%)为GSTP1(rs1695)AA基因型,102例(40.5%)为GSTP1(rs1695)AG基因型,7例(2.8%)为GSTP1(rs1695)GG基因型。经Hardy-Weinberg遗传平衡检验,证实本研究入组病例GSTP1(rs1695)基因具有群体代表性(P>0.05);8例Cerb-B-2(2+)和(2+→3+)者未行FJSH检测予以剔除,其中Luminal型占63.1%(154/244),三阴型占22.1%(54/244),Her-2过表达型占14.8%(36/244);GSTT1(-)在不同分子分型的乳腺癌人群中的分布不同,差异有统计学意义(P<0.05),而GSTM1和GSTP1(rs1695)基因多态性在各分子分型的乳腺癌人群中的分布差异无统计学意义(P>0.05)。结论 GSTT1基因多态性与乳腺癌的分子分型有关,GSTT1(-)在三阴型乳腺癌中缺失率较低,其基因多态性可为分子分型下乳腺癌的异质性提供合理补充。 Objective To investigate the distribution of GSTM1, GSTI'I and GSTP1 (rs1695) gene polymorphisms inpatients with breast cancer,and to analysis the relationship between three genes polymorphsms with molecular classification of breast cancer. Methods The gene polymorphisms of GSTM1 ,GSTI'I and GSTP1 (rs1695) were analyzed using multiply PCR technique and High Resolution Melting in 252 female breast cancers. Results In 252 cases of breast cancer,GSTM1 ( + ) genotype accounting for 42.9% (108/252) ,GSTM1 ( - ) genotype accounting for 57.1% (144/252) ;GSTrl ( + ) genotype accounting for 70.6% (178/252) ,GSTT1 ( - ) genotype accounting for 29.4% (74/ 252) ;GSTP1 (rs1695) AA genotype accounting for 56.7% (143/252), GSTP1 ( rs1695 ) AG genotype accounting for 40.5% ( 102/252 ), GSTP1 (rs1695) GG genotype accounting for 2.8% (7/252),GSTP1 (rs1695) enrolled into our research had a group representation (P 〉 0.05) suggested by the hardy - Weinberg test. 8 cases of Cerb - B - 2 expression (2 + ) and (2 + to 3 + ) were excluded because they were not verified by FJSH test,the Luminal subtype accounting for 63.1% (154/244) ,Triple negative subtype accounting for 22. 1% (54/244) ,Her -2 subtype accounting forl4.8% (36/244) ;there was statistic difference between GSTY1 polymorphism with molecular classification in breast cancers (P 〈0. 05 ),while there were no statistic difference between GSTM1, GSTP1 (rs1695) polymorphism with molecular classification in breast cancers (P 〉 0.05). Conclusion There was statistic difference between GSTI'I polymorphism with molecular classification in breast cancer,the GSTrl ( - ) rate accounting lower in Triple negative subtype. GSTrl polymorphism might provide reasonable supplement to Hetero- geneity of breast cancer.
出处 《宁夏医学杂志》 CAS 2014年第4期301-304,I0001,共5页 Ningxia Medical Journal
基金 宁夏银川市应用研究开发计划项目(2011029)
关键词 乳腺癌 乳腺癌分子亚型 免疫组化 高分辨融解曲线技术 基因测序 Breast cancer Breast cancer molecular subtype lmmunohistochemistry HRM Genc sequencing
  • 相关文献

参考文献13

  • 1Badve S, Turbin D, Thorat MA, et al. FOXA1 expression in breastcancer correlation with luminal sub -type A and survival [ J ]. Clin Cancer Res,2010,13 ( 15 ) :4415 -4421.
  • 2Zeng FF, Liu SY, Wei W, et al. Genetic polymorphisms of glutathi- one S - transferase T1 and bladder cancer risk:a meta analysis[ J]. Clin Exp Med ,2010,10:59 - 68.
  • 3胡夕春,王碧芸,邵志敏.2011年《St.Gallen早期乳腺癌初始治疗国际专家共识》与中国抗癌协会乳腺癌专业委员会指南之比较[J].中华乳腺病杂志(电子版),2011,5(4):8-9. 被引量:35
  • 4Fromowitz FB,Viola MV,Chao S,et al. Ras p21 expression in the pro- gression of breast cancer [ J ]. Hum Patho1,2007,18 ( 12 ) : 1268 - 1275.
  • 5乳腺癌HER2检测指南(2009版)[J].中华病理学杂志,2009,38(12):836-840. 被引量:193
  • 6Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes dealing with the diversity of breast cancer: highlights of the st gallen international expert consensus on the primary therapy of early breast cancer 2011 [ J ]. Ann Onco1,2011,22 ( 8 ) : 1736 - 1747.
  • 7Ihemelandu CU, Leffall LD, Dewitty RL, et al. Molecular breast cancer subtypes in premeno - pausal and postmenopausal African - American women : age - specific prevalence and survival [ J ]. Surg Res,2010,143:109 - 118.
  • 8Hugh J, Hanson J, Cheang MC,et al. Breast cancer subtypes and re- sponse to docetaxel in node -positive breast cancer: use of an im- munohistochemical definition in the BCIRG 001 trim [ J ]. J C|in onco1,2009,27 ( 8 ): 1168 - 1176.
  • 9Oakley A. Glutathione transferases: a structural perspective [ J ]. Drag Metab Rev,2011,43 :138 - 151.
  • 10Hayes JD, Strange RC. Glutathione S - transferase polymorphisms and their biological consequences [ J ]. Pharmacology, 2000,61 : 154 - 166.

二级参考文献26

  • 1<乳腺癌HER2检测指南>编写组,霍临明.乳腺癌HER2检测指南[J].中华病理学杂志,2006,35(10):631-633. 被引量:164
  • 2Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol, 2007,25 ( 33 ) : 5287-5312.
  • 3Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol,2007,25( 1 ) :118-145.
  • 4Hanna WM, Kwok K. Chromogenic in-situ hybridization: a viable alternative to fluorescence in-situ hybridization in the HER2 testing algorithm. Mod Pathol,2006,19(4) :481-487.
  • 5Gong Y, Sweet W, Duh YJ, et al. Chromogenic in situ hybridization is a reliable method for detecting HER2 gene status in breast cancer: a multicenter study using conventional scoring criteria and the new ASCO/CAP recommendations. Am J Clin Pathol,2009,131 (4) :490-497.
  • 6Dietel M, Ellis IO, Hofler H, et al. Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists. Virchows Arch ,2007,451 ( 1 ) : 19-25.
  • 7Pedersen M, Rasmussen BB. The correlation between dual-color chromogenic in situ hybridization and fluorescence in situ hybridization in assessing HER2 gene amplification in breast cancer. Diagn Mol Pathol,2009,18 (2) :96-102.
  • 8Yaziji H, Gown AM. Accuracy and precision in HER2/neu testing in breast cancer: are we there yet? Hum Pathol, 2004, 35 (2): 143-146.
  • 9Sauter G, Lee J, Bartlett JM, et al. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologie considerations. J Clin Oncol, 2009,27 (8) : 1323- 1333.
  • 10Rhodes A, Jasani B, Anderson E, et al. Evaluation of HER-2/ neu immunohistochemical assay sensitivity and scoring on formalin-fixed and paraffin-processed cell lines and breast tumors: a comparative study involving results from laboratories in 21 countries. Am J Clin Pathol,2002,118 (3) :408-417.

共引文献228

同被引文献86

  • 1王丹,刘殿武,翟俊霞.肿瘤类疾病风险与谷胱甘肽转硫酶T1基因多态性的关系--Meta分析的国际文献研究[J].医学信息(医学与计算机应用),2016,29(26):1-2. 被引量:1
  • 2吴逢波,陈泽莲,徐珽,唐尧.CYP2C9基因多态性与合理用药研究[J].中国药房,2007,18(29):2308-2309. 被引量:11
  • 3许建明.急性药物性肝损伤诊治建议(草案)[J].中华消化杂志,2007,27(11):765-767. 被引量:348
  • 4Fan L, Strasser-Weippl K, Li J J, et al. Breast cancer in China [J]. Lancet Oncol, 2014,15(7) :e279 -89.
  • 5Goldhirsch A, Wood W C, Coates A S, et al. Strategies for sub- types-dealing with the diversity of breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy ofearly breast cancer 2011 [ J ]. Ann Oncol, 2011,22 (8) : 1736 - 47.
  • 6Cheang M C, Chia S K, Voduc D, et al. Ki-67 index, HER2 sta- tus, and prognosis of patients with Luminal B breast cancer[ J]. J Natl Cancer Inst, 2009,101 (10) :736 - 50.
  • 7van Minekwitz G, Untch M, Blohmer J U, et al. Definition and impact of pathologic complete response on prognosis after neoadju- rant chemotherapy in various intrinsic breast cancer subtypesE J]. J Clin Oncol, 2012,30 ( 15 ) : 1796 - 804.
  • 8Chen X S, Wu J Y, Huang O, et al. Molecular subtype can pre- dict the response and outcome of chinese locally advanced breast cancer patients treated with preoperative therapy[ J ]. Oncol Rep, 2010,23(5) :1213 -20. 2014,30(1) :10 -4.
  • 9Widodo I, Dwianingsih E K, Triningsih E, et al. Clinicopatholog- ieal features of indonesian breast cancers with different molecular subtypes[J]. Asian Pae J Cancer Prey, 2014,15 ( 15 ) :6109 - 13.
  • 10Hugh J, Hanson J, Cheang M C, et al. Breast cancer subtypes and response to doeetaxel in node-positive breast cancer : use of an immunohistochemical definition in the BCIRG 001 trial[ J]. J Clin Oncol, 2009,27 ( 8 ) : 1168 - 76.

引证文献8

二级引证文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部